A novel chimeric coronavirus spike vaccine combining SARS-CoV-2 RBD and scaffold domains from HKU-1 elicits potent neutralising antibody responses
Veronica Zoest(The University of Melbourne), Hyon‐Xhi Tan(The University of Melbourne), Robyn Esterbauer(The University of Melbourne), Karen Hughes(Bangor University), Marianne Gillard(The University of Queensland), Merle Dayton(Walter and Eliza Hall Institute of Medical Research), Hannah G. Kelly(Peter MacCallum Cancer Centre), Isaac Barber-Axthelm(University of Washington), Wai‐Hong Tham(The University of Melbourne), Martina L. Jones(The University of Queensland), Jennifer A. Juno(The University of Melbourne), Adam K. Wheatley(The University of Melbourne), Stephen J. Kent(The University of Melbourne), Marc Pellegrini(The University of Melbourne), Benjamin Hughes(The University of Queensland), Wen Shi Lee(The University of Melbourne), Phillip Pymm(The University of Melbourne), James P. Cooney(The University of Melbourne), Kathryn C. Davidson(Australian Regenerative Medicine Institute), Andrew P. Kelly(The University of Melbourne), Lauren Burmas(The University of Melbourne), Lydia Murdiyarso(The University of Melbourne), Courtney E. McAleese(The University of Queensland)
Cited by 1
Related Papers
Mechanism and inhibition of the papain‐like protease, PLpro, of SARS‐CoV‐2
|The EMBO Journal|2020|499
Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19
|Nature Medicine|2020|490